ADAR1 Capital Management LLC Acquires Shares of 99,600 Sanofi (NASDAQ:SNY)

ADAR1 Capital Management LLC purchased a new stake in shares of Sanofi (NASDAQ:SNY - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 99,600 shares of the company's stock, valued at approximately $4,804,000. Sanofi accounts for about 1.0% of ADAR1 Capital Management LLC's portfolio, making the stock its 26th biggest holding.

Several other hedge funds have also added to or reduced their stakes in SNY. Charles Schwab Investment Management Inc. grew its stake in shares of Sanofi by 31.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company's stock worth $8,040,000 after purchasing an additional 33,105 shares during the period. HighTower Advisors LLC grew its position in shares of Sanofi by 1.0% during the 3rd quarter. HighTower Advisors LLC now owns 88,100 shares of the company's stock worth $5,081,000 after buying an additional 848 shares during the period. IHT Wealth Management LLC acquired a new position in shares of Sanofi during the 3rd quarter worth about $227,000. Stifel Financial Corp increased its stake in shares of Sanofi by 2.0% in the 3rd quarter. Stifel Financial Corp now owns 562,547 shares of the company's stock valued at $32,420,000 after acquiring an additional 10,892 shares during the last quarter. Finally, State Street Corp raised its position in shares of Sanofi by 0.5% in the 3rd quarter. State Street Corp now owns 56,734 shares of the company's stock valued at $3,270,000 after acquiring an additional 264 shares during the period. Institutional investors own 14.04% of the company's stock.

Analyst Ratings Changes

Several analysts recently commented on SNY shares. Deutsche Bank Aktiengesellschaft raised Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. Sanford C. Bernstein raised Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. Finally, The Goldman Sachs Group started coverage on Sanofi in a research report on Friday, March 21st. They issued a "neutral" rating and a $65.00 price objective for the company. Three analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $62.50.

Remove Ads

Sanofi Stock Up 3.7 %

Shares of NASDAQ:SNY traded up $1.84 during trading on Friday, hitting $51.50. 3,191,009 shares of the company were exchanged, compared to its average volume of 2,324,450. The stock has a market cap of $130.10 billion, a price-to-earnings ratio of 20.68, a P/E/G ratio of 1.01 and a beta of 0.57. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $60.12. The firm has a fifty day moving average price of $54.97 and a two-hundred day moving average price of $52.38.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. As a group, research analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.